Clinicians

Alzheimer’s Trials Are Finally Blood-Gated

MS Regulators Are No Longer Reading the Same Risk

Europe Can Forecast Vibrio Risk. It Still Has To Act.

Cardiology has too many dashboards. The danger is forgetting the patient

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up

A CE Mark Is Not Access

Europe Opens the SMA Gene-Therapy Door Wider

ALS Needs Proof, Not Just Another Biomarker

Pregnancy complications demand long-term cardiovascular care
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
